ArticleGlycoconjugate journal2026
Enhanced anti-proliferative activity of Jacalin, a plant lectin in combination with taxol in MDA-MB-468 triple-negative breast cancer cells.
Article in Glycoconjugate journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Plant lectins derived from a variety of plant sources can inhibit the proliferation of certain types of human cancer cells and have been studied extensively. In the present study, the effects of Jacalin, a Thomsen–Friedenreich disaccharide-binding lectin isolated from jackfruit seeds, on the triple-negative breast cancer (TNBC) cell line MDA-MB-468 was investigated in combination with Taxol. It was observed that Jacalin inhibited the proliferation of these cancer cells. The antiproliferative effect of Jacalin on MDA-MB-468 was found to be reversible. However, when Jacalin was removed from the cell culture after the treatment for the given time, the cancer cells recovered back and started proliferating again. Importantly, Jacalin has minimum effect on PBMCs proliferation taken as primary cell line control. Additionally, MDA-MB-468 cells were treated with a combination of Taxol (25 µM) and Jacalin (40 µg/mL). This shows that Jacalin and Taxol work better when used together, leading to a stronger inhibition in cancer cell growth. These results suggest that Jacalin shows in-vitro potential and requires further mechanistic and in-vivo evaluation before therapeutic relevance can be established.
Indexed as
Identifiers
41784918What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.